$LLY — WATCHLIST 📊

$LLY — WATCHLIST 📊 Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. 🎯 Q1 FY26 | Rev $20B | EPS $8.55 vs $6.79 🟢 💡 Consensus and the market are pricing in sustained high growth and premium multiples. The variant view is that the current multiple is unsustainable and any disappointment—slower growth, pipeline setbacks, or sector rotation—will trigger sharp P/E compression toward sector norms, as seen in historical analogs for mega-cap pharma trading at >2x peer... 📉 Reward/Risk: 0.7:1 🏢 Business Quality: 9/10 - Exceptional pipeline (obesity, diabetes, Alzheimer's), market leadership in high-growth areas, strong revenue growth (+55.5% YoY), high net margins (37.4%), and robust cash flows. Also in play: $NVO $PFE $MRK $JNJ $ABBV $BMY

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.